RISK-BASED MONITORING (RBM), A MECHANISM TO OPTIMIZE CLINICAL TRIAL MONITORING PROCESS

Life sciences organizations are faced with a multitude of challenges:

- Increased pressure on pharmaceutical companies to improve time-to-market and optimize cost
- Pressure to lower cost of clinical trials without compromising on quality
- Need to improve efficiency of the entire clinical trial monitoring value chain and reduce 100% dependency on Source Data Verification (SDV).
- Need to improve visibility into different dimensions of study-data

The Infosys RBM solution attempts to improve the clinical and commercial success for life sciences organizations. It helps organizations to focus on critical study-parameters and relies on a combination of remote and onsite monitoring. The solution has built-in predictive analytical capabilities, and uses statistical modeling and machine learning techniques to provide early insights into risks for a variety of predetermined categories for the ongoing trials.

![Diagram](image-url)

**Salient features:**

- Uses risk-based, critical data focus
- Central/near real-time monitoring
- Predictive Analytics driven by pattern matching, machine learning, and clustering algorithms
- NLP-based components used to mine text and extract relevant data from past reports, both structured and unstructured
- Visualization Engine to provide better insights into the data analysis
- Technology solution scalable, extensible, and with the ability to process large amounts of data
Predictive Analytics of Risk Management

The predictive analytics component extracts data from clinical data repository. It uses pattern matching, statistical modeling, and machine learning methods to build appropriate models for predetermined categories that need to be predicted, for example, patient dropouts. During model execution, data for ongoing clinical trials is acquired and used for predicting the outcome of different risk categories (site, demographics, dropouts, etc.)

<table>
<thead>
<tr>
<th>Step</th>
<th>Input</th>
<th>Methodology</th>
<th>Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Past Data</td>
<td>Build Model</td>
<td>Refine Models</td>
</tr>
<tr>
<td>Patterns from past data</td>
<td>Clinical Data Repository (OC/RDC ClinTrial/InForm)</td>
<td>Training Set</td>
<td>Visualization at Country, Site, and CRO levels</td>
</tr>
<tr>
<td>2</td>
<td>Current Trial Information</td>
<td>Execute Model</td>
<td></td>
</tr>
<tr>
<td>Predict risks in current trial</td>
<td>CTMS, LIMS, IVRS, PCV</td>
<td>Use available models to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Predict occurrence of various risk categories</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Assign risk levels</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Visualize at various levels - Country, Site, CRO, etc.</td>
<td></td>
</tr>
</tbody>
</table>

Solution Benefits

- Allows early diagnosis of risks during design, conduct, and close out of clinical interventional studies
- Pulls in data and metrics from trial management systems, CDM systems, as well as Safety management systems, offering a 360° view of risks
- Reporting of risks during trial conduct (study, site, and patient levels) that helps in recalibrating the risk profile of a site
- Predictive analytics engine to support clinical trial risk management

For more information, contact askus@infosys.com

© 2018 Infosys Limited, Bengaluru, India. All Rights Reserved. Infosys believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Infosys acknowledges the proprietary rights of other companies to the trademarks, product names and other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Infosys Limited and/or any named intellectual property rights holders under this document.